
    
      Patient Population:

      Thoracic esophageal cancer able to tolerate tri-modality therapy; Clinical stage T3-4, N0-1,
      M0

      Scheme:

      Patients are randomized to 2 arms:

      Arm A:

      Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate
      paclitaxel/carboplatin 2 cycles.

      Arm B:

      Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate
      paclitaxel/carboplatin 2 cycles.
    
  